Investor Presentaiton

Appendix A CSL Behring - Key Products CSL BEHRING Therapy Group Sales $m Change1% HY24 Revenue By Therapy Group $m Privigen IVIG 1,768 35% Hizentra SCIG 945 18% 9% Other Specialty $450 4%, Other, $242 Albumin Albumin 613 8% 10%, Peri-Operative 35% IVIG Idelvion Haemophilia 390 7% Kcentra Specialty 366 12% Haegarda Specialty 245 9% Berinert Specialty 120 (7%) Bleeding, $526 4%, Plasma, $205 8% Recombinants $445 $1,812 Haemocomplettan Specialty 115 0% Humate Haemophilia 97 8% 12%, 18%, Albumin, $613 SCIG, $945 Haemate Haemophilia 58 16% 1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail 23 Driven by Our Promise CSL

View entire presentation